Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Todd Arnedt, PhD, professor of psychiatry and neurology at Michigan Medicine-University of Michigan, joins the podcast to discuss the recently published American Academy of Sleep Medicine clinical practice guideline on combination treatment for chronic insomnia disorder in adults. Arnedt explains the rationale behind formal recommendations for concurrent use of cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, particularly as combination treatment becomes increasingly common in clinical practice.

The conversation reviews the evidence supporting CBT-I as the preferred foundational treatment approach, where combination therapy may offer advantages over pharmacotherapy alone, and how clinicians should think about factors such as symptom burden, treatment goals, access to CBT-I, and patient preference when selecting treatment strategies. Arnedt also outlines ongoing research gaps involving sequential treatment approaches, medication classes, long-term outcomes, and personalized insomnia care.

Looking for more Sleep Disorders discussion? Check out the NeurologyLive® Sleep Disorders clinical focus page.

Episode Breakdown:

• 1:15 – Why formal insomnia combination treatment guidance was needed
• 2:45 – Defining concurrent CBT-I and pharmacotherapy approaches
• 4:35 – Evidence supporting CBT-I as foundational insomnia treatment
• 7:15 – Situations where combination therapy may improve patient outcomes
• 7:50 – Neurology News Network
• 10:20 – Patient-specific factors influencing insomnia treatment selection
• 12:30 – Barriers involving CBT-I access, cost, and real-world implementation
• 16:55 – Research gaps surrounding sequencing, long-term outcomes, and personalization

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease
• FDA Grants Priority Review to Bayer’s Asundexian for Secondary Stroke Prevention
• Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Scott Grossman, MD, assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine, discusses emerging research on inter-eye retinal nerve fiber layer (RNFL) asymmetry as a biomarker of prior optic neuritis in pediatric-onset multiple sclerosis (POMS). Drawing from data presented at the 2026 American Academy of Neurology Annual Meeting, Grossman explains how optical coherence tomography (OCT) may help improve diagnostic confidence in pediatric MS by identifying remote optic nerve injury, while also outlining how a 4-micron inter-eye RNFL difference emerged as the optimal threshold in this cohort. The conversation also explores the role of OCT within the updated 2024 McDonald Criteria, the feasibility of integrating OCT into routine neurology practice, challenges surrounding normative pediatric OCT data, and future research directions involving visible light OCT and broader population datasets.

Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page.

Episode Breakdown:

• 1:15 – Optic nerve involvement and updated MS diagnostic criteria
• 3:20 – Pediatric RNFL asymmetry thresholds and interpretation of study findings
• 5:15 – Clinical implications of OCT biomarkers in pediatric-onset MS
• 6:40 – Neurology News Network
• 8:40 – Feasibility of incorporating OCT into neurology and MS practice
• 10:15 – Future research directions, including normative data and visible light OCT

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation
• FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
• Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this Mind Moments episode, Greg Pontone, MD, Chief of Aging Behavioral and Cognitive Neurology at the University of Florida, joins the podcast to discuss the interplay between cognition and Parkinson disease, with a focus on how clinicians can better recognize and manage cognitive changes across the disease course. Pontone outlines the prevalence of early cognitive impairment, noting that a significant proportion of patients may present with subtle deficits at diagnosis, particularly in executive function and processing speed.

The conversation explores the impact of commonly used medications on cognition, including anticholinergics and benzodiazepines, and how clinicians can balance therapeutic benefit with cognitive risk. Pontone also reviews current treatment strategies, including cholinesterase inhibitors and memantine, while emphasizing the importance of nonpharmacologic approaches such as structured routines and cognitive training. Additional discussion highlights the evolving role of biomarkers, the overlap between Parkinson disease and Alzheimer pathology, and the need for earlier recognition, better patient education, and continued research to improve long-term cognitive outcomes in this population.

Looking for more Movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.

Episode Breakdown:

• 1:10 – Prevalence and early signs of cognitive impairment in Parkinson disease
• 2:30 – Medication-related cognitive effects and contributing drug classes
• 4:20 – Balancing therapeutic benefit vs cognitive risk in treatment decisions
• 6:05 – Current treatments for cognition, including pharmacologic and behavioral strategies
• 10:25 – Neurology News Network
• 13:00 – Role of biomarkers and Alzheimer overlap in Parkinson cognition
• 15:45 – Future priorities for advancing cognitive care and research in PD

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Clears Cala kIQ Plus for Essential Tremor and Parkinson Disease Hand Tremor
• FDA Issues Complete Response Letter for GTx-104 in Patients With Aneurysmal Subarachnoid Hemorrhage
• Satralizumab Meets Primary End Point in Phase 3 METEOROID Study in MOGAD